Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

Thematic (Sector/Industry)

<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/016/178/original/download%20%281%29.jpg?1478808170" class="editor-image img-responsive" data-smartkarma-image-id="16178"></figure><div class="content-caption">(I thought it was a reality show till I was shown the Oval Office today!)</div>Now that the initial shock period is over, we return to finding out how President Trump could affect the U.S. (and with it the global) healthcare and pharmaceutical sector. Broadly, Trump's policy on healthcare has focused on two issues: allowing Medicare to negotiate drug prices directly with the drug companies and repealing Obamacare.<div class="content-highlight">Drug Pricing and Trump:</div>Allowing Medicare and similar U.S. government programs to…

(I thought it was a reality show till I was shown the Oval Office today!)Now that the initial shock period is over, we return to finding out how President Trump could affect the U.S. (and with it the global) healthcare and pharmaceutical sector. Broadly, Trump's policy on healthcare has focused on two issues: allowing Medicare to negotiate drug prices directly with the drug companies and repealing Obamacare.Drug Pricing and Trump:Allowing Medicare and similar U.S. government programs to…

President Trump and Healthcare (And Pharma) Sector: What's Next?

Bespoke Research on China and neighbouring regions, Bixmoor

Bixmoor

Bespoke Research on China and neighbouring regions

Bixmoor specialises in providing bespoke research to business, governments and the financial community on China and neighbouring regions. We seek to build long-term relationships with our clients, based on our expertise, our reliability and our determination to find the right solution.

A comprehensive world survey of population heights over the last century has thrown up some surprising results. Americans have had the smallest height gain of any developed country, whereas Koreans have grown by an average of six inches over the last 100 years.

A comprehensive world survey of population heights over the last century has thrown up some surprising results. Americans have had the smallest height gain of any developed country, whereas Koreans have grown by an average of six inches over the last 100 years. 

European Event-Driven Analyst

Jesus Rodriguez Aguilar

Event-Driven

<ul>
<li>March saw broad-based tightening across Europe’s dual-class universe, reversing February’s dispersion widening. Both the median and mean moved towards convergence, driven by retracement in structurally wide spreads.</li>
<li>Liquidity-Driven convergence reasserted itself in Fuchs, Carlsberg, Grifols and Sixt, while Handelsbanken remained the dominant structural anomaly despite meaningful tightening.</li>
<li>Telecom Italia continues to behave as a dividend-anchored structure, but with the approved savings conversion, convergence is increasingly shaped by corporate action rather than pure market arbitrage.</li>
</ul>


March saw broad-based tightening across Europe’s dual-class universe, reversing February’s dispersion widening. Both the median and mean moved towards convergence, driven by retracement in structurally wide spreads.
Liquidity-Driven convergence reasserted itself in Fuchs, Carlsberg, Grifols and Sixt, while Handelsbanken remained the dominant structural anomaly despite meaningful tightening.
Telecom Italia continues to behave as a dividend-anchored structure, but with the approved savings conversion, convergence is increasingly shaped by corporate action rather than pure market arbitrage.


Liquid Universe of European Ordinary and Preferred Shares: March '26 Report

<ul>
<li>
February saw dispersion widen modestly, with the median stable but the mean rising as structural right-tail spreads re-expanded.</li>
<li>Liquidity-Driven convergence worked selectively (Carlsberg, Fuchs), reinforcing the episodic nature of ord/pref tightening.</li>
<li>Structural anomalies persist, with Danieli widening and Handelsbanken remaining the universe’s dominant dispersion outlier.</li>
</ul>



February saw dispersion widen modestly, with the median stable but the mean rising as structural right-tail spreads re-expanded.
Liquidity-Driven convergence worked selectively (Carlsberg, Fuchs), reinforcing the episodic nature of ord/pref tightening.
Structural anomalies persist, with Danieli widening and Handelsbanken remaining the universe’s dominant dispersion outlier.


Liquid Universe of European Ordinary and Preferred Shares: February '26 Report

<ul>
<li>January saw post year-end normalisation, with selective convergence resuming while the median voting premium remained stable, confirming no systemic repricing of control across Europe’s dual-class universe.</li>
<li>Liquidity and structure drove outcomes, with convergence working in scalable, index-exposed pairs, while a small number of structurally constrained names continued to dominate dispersion.</li>
<li>Opportunities remain selective into 2026, favouring liquidity-driven convergence and balance-sheet normalisation, while extreme Nordic dislocations persist as high-dispersion, structurally constrained trades.</li>
</ul>


January saw post year-end normalisation, with selective convergence resuming while the median voting premium remained stable, confirming no systemic repricing of control across Europe’s dual-class universe.
Liquidity and structure drove outcomes, with convergence working in scalable, index-exposed pairs, while a small number of structurally constrained names continued to dominate dispersion.
Opportunities remain selective into 2026, favouring liquidity-driven convergence and balance-sheet normalisation, while extreme Nordic dislocations persist as high-dispersion, structurally constrained trades.


Liquid Universe of European Ordinary and Preferred Shares: January '26 Report

Spain

Grifols S.A. develops, manufactures, and markets plasma derivatives, IV Therapy, enteral nutrition, diagnostic systems, and medical materials.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Grifols SA (GRF SM)

President Trump and Healthcare (And Pharma) Sector: What's Next?

Now that the initial shock period is over, we return to finding out how President Trump could affect the U.S. (and with it the global) healthcare...

Dr. Bhavneesh Sharma, MD, MBA

A 'heads Up' on Changing World Heights

A comprehensive world survey of population heights over the last century has thrown up some surprising results. Americans have had the smallest...

Bixmoor

Liquid Universe of European Ordinary and Preferred Shares: March '26 Report

March saw convergence across European dual-class shares, with dispersion narrowing as liquidity returned. Structural outliers persist, while...

Jesus Rodriguez Aguilar

Liquid Universe of European Ordinary and Preferred Shares: February '26 Report

February brought mild widening in Europe’s dual-class spreads, but no systemic repricing of voting rights. Dispersion remains driven by structural...

Jesus Rodriguez Aguilar

Liquid Universe of European Ordinary and Preferred Shares: January '26 Report

January confirmed dispersion without repricing in European dual-class stocks: liquidity and structure drove selective convergence, while a few...

Jesus Rodriguez Aguilar

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)